Themis Medicare Ltd Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
No
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The hospital segment is expected to see significantly higher growth in the second half of the year compared to the first half, driven by de-bottlenecking and improved supply capabilities.
- New product launches, such as Remithem, are anticipated to boost sales and expand market presence, especially in hospitals.
- The domestic hospital and trade (branded) businesses contributed notably to recent growth, with trade domestic business growing 35-40%.
- Growth is expected to sustain and improve in the domestic market as the company leverages its established distribution network and expands product offerings.
- Marketing investments aim to increase doctor touchpoints and product portfolio in hospitals without increasing fixed costs, focusing on productivity over headcount growth.
- The company foresees no major capacity expansion capex soon, relying on contract manufacturing to meet rising demand.
- Long-term strategy includes expanding into women’s healthcare and other hospital specialties for diversified growth.
See what Themis Medicare Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no specific mention of any current or planned new fundraising through debt or equity in the call transcript.
- The company stated that they have not planned any capital expenditure (capex) for capacity expansion in the next few years, indicating no immediate need for fundraising for expansion.
- The API business is being transferred to a wholly-owned subsidiary to focus and streamline growth; no fundraising related to this is indicated.
- The company emphasized reliance on contract manufacturing to meet demand instead of investing in new manufacturing capacity.
- They are focusing on improving productivity and marketing within existing resources.
- No explicit plans for issuing new equity or raising debt were discussed during this period.
See what Themis Medicare Ltd management said on order book — free account, 30 seconds.
Capex plans
No- No significant planned capex for capacity expansion over the next few years; current production can be met through contract manufacturing facilities.
- Investment focus is on increasing productivity and marketing efforts rather than expanding manpower or fixed capacity.
- The company has set up a small R&D unit in Gujarat (Baroda) to work on certain molecules not permitted in existing facilities; this is not a manufacturing unit.
- Strategic investment is focused on expanding product offerings in hospital business, leveraging existing distribution networks.
- Capital allocation is more towards varied marketing expenditure to promote new products, especially in hospital and trade segments.
- The transfer of API business to a wholly-owned subsidiary aims at enabling focused growth and capital efficiency but does not involve new capital expenditure.
- Overall, growth strategy prioritizes variable marketing and R&D investments over fixed capital spending.
Track Themis Medicare Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- Hospital segment expected to experience significantly higher growth in the second half of FY ’24 due to resolved supply constraints and new product launches (e.g., Remithem).
- Strong focus on increasing hospital product basket and doctor touchpoints to drive revenue without significantly increasing fixed costs.
- EBITDA margin pressure due to raw material price increases (API costs) and manpower additions in hospital business; improvements expected as new API manufacturing routes are adopted and operational productivity rises.
- Long-term strategy includes investing more in marketing, which may temporarily depress margins but should drive top-line growth.
- API business transfer to a subsidiary to streamline focus and growth expected to benefit overall financials.
- EPS showed growth with H1 FY ’24 EPS at INR32.07 and quarter EPS at INR12.30, expected to improve with margin recovery and revenue growth.
Order book
- The transcript does not specifically mention the current or expected order book or pending orders for Themis Medicare Limited.
- However, it highlights a strong momentum in the hospital segment with 20% growth in Q2 FY’24 and expectations of even higher growth ahead.
- The company has completed de-bottlenecking to meet demand, implying a readiness to fulfill existing and future orders.
- Multiple new product launches, including Remithem (Remifentanil) and others, are expected to boost hospital business growth.
- Investments in expanding the hospital team and marketing efforts signal increasing capacity to handle more orders.
- Contract manufacturing partnerships indicate preparation to meet rising demand without capex expansion.
- Overall, while exact orderbook numbers aren't given, the company is positioned for a robust increase in order flow and execution going forward.
How does Themis Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Themis Medicare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Themis Medicare Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…